Lv75
3969 积分 2021-07-15 加入
Why is Biomarker Assay Validation Different from that of Pharmacokinetic Assays?
15天前
已完结
Commercialization of Cell Therapies: A CDMO Perspective
16天前
已完结
Incorporation of target safety review in drug discovery
18天前
已关闭
Overcoming solid-tumor barriers: armored CAR-T cell therapy
18天前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
18天前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
18天前
已完结
The Society for Immunotherapy of Cancer Perspective on Tissue-Based Technologies for Immuno-Oncology Biomarker Discovery and Application
26天前
已完结
Results from an EFPIA, JPMA, PhRMA industry survey on reopening and revamping the ICH S7A guidance on safety and secondary pharmacology
26天前
已完结
Impact of degradation in subcutaneous tissue and lymphatic fluid on absorption of Fc-fusion proteins following subcutaneous administration
26天前
已完结
Off-target Effects of Oligonucleotides and Approaches of Preclinical Assessments
27天前
已完结
皖公网安备34019202002308
